Lisdexamfetamine granted approval for ADHD in adults

The FDA approves simulant prodrug for treatment of adult ADHD

An often overlooked group of patients with Attention Deficit Hyperactivity Disorder (ADHD) is adults. But now this population has a new choice of treatment. Shire plc has announced the approval of lisdexamfetamine dimesylate (Vyvanse) for the treatment of ADHD in adults. The once-daily drug was originally approved by the FDA in July 2007 for the treatment of ADHD in children aged six to 12 years old. Lisdexamfetamine is an inactive prodrug that is bonded to l-lysine. Once ingested, it is converted into its active form, d-amphetamine. The product is currently available in 30-mg, 50-mg, and 70-mg strengths.